KORU Medical Systems (KRMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

KORU Medical Systems

NasdaqCM•Healthcare•Medical Instruments & Supplies

$3.25+0.03(0.01%)Market closed

Market Cap

$147.47M

P/S

3.3x

P/B

8.2x

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

How this company scores

GoodMetricSide Score: 67/100

Strongest: Growth (22/25); weakest: Cash & Earnings Quality (13/25).

Profitability17/25

Growth22/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality13/25

Strengths

Growing revenueLong cash runwayInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 3.3x5y range 3.3x – 6.4x

Currently near its 20-quarter median.

P/B · 8.2x5y range 3.0x – 15.4x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $147.47M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $45.11M
Q. Revenue: $12.05M
TTM EBITDA: $-861,497
TTM Op. Income: $-1.65M
Q. Op. Income: $626,991
TTM Net Income: $-1.82M
Q. Net Income: $252,449
EPS: $0.01
Shares Out.: $46.08M

$45.11M in TTM revenue grew 22.4% YoY, reaching $12.05M last quarter. TTM EBITDA of $-861,497 and TTM operating income of $-1.65M show growth is flowing through to the bottom line. However, net income is negative at $1.82M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 65.1%
EBITDA Margin: 6.9%
Op. Margin: 5.2%
Net Margin: 2.1%

Op. margin of 5.2% is up 8.3% YoY — cost efficiency is improving. Net margin at 2.1% and gross margin of 65.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 270% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.3x
P/B Ratio: 8.2x

P/S of 3.3x and P/B of 8.2x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $27.96M
Cash: $8.29M
Long-Term Debt: N/A
Book Value: $18.05M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $216,113
TTM Free Cash Flow: $776,653
FCF Margin: 1.7%
FCF / Net Income: -0.4

TTM FCF of $776,653 on $216,113 in operating cash flow. The FCF / Net Income ratio of -0.4x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.